Latest Breaking News On - Connie peyrottes - Page 1 : comparemela.com

CER-001 identified as potential treatment for septic patients

A Phase II pilot study demonstrated CER-001 is a potentially game-changing treatment for septic patients at high risk of acute kidney injury.

ABIONYX Pharma Reports Positive Results from Phase 2a Pilot Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury

Positive results on primary and secondary endpoints, identifying dose for future development Direct and significant effect of CER-001 on endotoxin removal and consequent reduction in the inflammatory

ABIONYX Pharma Reports Positive Interim Results From Phase 2a Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury

Rapid reversal of cytokine storm in septic patients Enhanced resolution of biomarkers for inflammation including leukocytosis compared to standard of care No treatment-related serious

ABIONYX Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury

ABIONYX Pharma: ABIONYX Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury

ABIONYX Pharma: ABIONYX Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury Temporary Authorization for Named Use (ATUn) showed promising efficacy in renal diseases Evaluation of the clinical activity by dosage level of CER-001 in the prevention of Acute Kidney Injury in ICU patients with septicemia A potentially modifying effect on the progression of the inflammatory cascade in sepsis Pending positive data, the company aims to move into Phase 2b by end of 2021 Regulatory News: ABIONYX Pharma ( FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces that it has received authorization from the Italian authorities to launch a clinical trial named